Zobrazeno 41 - 50
of 2 157
pro vyhledávání: '"59"'
Publikováno v:
Blood. 134:5492-5492
Introduction To date, various biochemical markers of bone remodeling have been investigated in multiple myeloma (MM) patients. Serum C-terminal telopeptide of type I collagen (sICTP) is a well-known biochemical marker of bone remodeling. Although sev
Autor:
Michele Donato, Scott D. Rowley, Pashna N. Munshi, Ronit Reich-Slotky, Noa Biran, Stuart L. Goldberg, Sarah Makhani, David S. Siegel, David H. Vesole, Andrew L. Pecora
Publikováno v:
Blood. 134:4475-4475
Background: Salvage autologous hematopoietic stem cell transplantation (HSCT) is an effective treatment for patients with relapsed multiple myeloma (MM). Adequate HPSC after multiple cycles of dose-intense melphalan (mel) can be harvested, cryopreser
Autor:
Jooryung Huh, Ah Ra Jung, Eun Jin Chae, Jin Roh, Cheolwon Suh, Chan-Sik Park, Kyoung Won Kim, Jin-Sook Ryu, Hyungwoo Cho, Yoon Sei Lee, Sang-wook Lee, Dok Hyun Yoon, Hyo-Kyung Pak
Publikováno v:
Blood. 134:2895-2895
Introduction Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease that can be characterized by distinct pathologic subtypes, morphologic variants, and gene expression profiles. Co-expression of MYC and BCL2 proteins by immunohistochemistr
Autor:
Tony Reiman, Eshetu G. Atenafu, Richard Leblanc, Esther Masih-Khan, Christopher P. Venner, Michael Sebag, Arleigh McCurdy, Rami Kotb, Donna E. Reece, Hannah Cherniawsky, Muhammad Aslam, Darrell White, Victor H Jimenez-Zepeda, Julie Stakiw, Engin Gul, Kevin W. Song, Martha L Louzada
Publikováno v:
Blood. 134:3173-3173
BACKGROUND: Phase 3 trials and a meta-analysis have demonstrated that Lenalidomide (Len) administration as maintenance improves the PFS and OS after ASCT performed as part of 1st line therapy. In addition, retrospective and registry studies have sugg
Publikováno v:
Blood. 134:3315-3315
Background Patients with peripheral T cell lymphomas (PTCLs) generally have a poor prognosis with conventional chemotherapy. Most studies demonstrates that, compared to the patients who did not achieve complete remission (CR) after initial therapy, t
Autor:
Ashok K. Vaid, Aseem Khurana, Suman S Karanth, Bhuvan Chugh, Nitin Sood, Saurabh Mishra, Gautam Dheeraj, Ashok Sen
Publikováno v:
Blood. 134:5350-5350
Background: Diffuse Large B cell Lymphoma (DLBCL) accounts for nearly 25% of all Non-Hodgkin's lymphoma (NHL) in the developed world, making it the most common lymphoma. With the diversities in clinical presentation, morphology, molecular and genetic
Autor:
Francesco Buccisano, Ulrich Germing, Antonella Poloni, Elena Crisà, Bruno Martino, Enrico Balleari, Alfredo Molteni, Valeria Santini, Anna Marina Liberati, Pierre Fenaux, Caterina Alati, Giorgina Specchia, Stefana Impera, Dario Ferrero, Roberto Latagliata, Marta Riva, Monica Bocchia, Pasquale Niscola, Esther Oliva, Maria Teresa Voso, Giuseppe A. Palumbo, Isabella Capodanno, Gianluigi Reda, Maria Grazia D'Errigo, Stefano Mancini, Anna Candoni, Patrizia Cufari, Prassede Salutari, Grazia Sanpaolo, Gina Zini, Valentina Giai
Publikováno v:
Blood. 134:3000-3000
Background: In myelodysplastic syndromes (MDS), thrombocytopenia is associated with mortality and treatments in this setting are scarce. We tested whether eltrombopag, a thrombopoietin receptor agonist, be effective in improving outcomes in lower-ris
Autor:
Matt Kalaycio, Cassandra M Kerr, Hetty E. Carraway, Sanghee Hong, Anjali S. Advani, Betty K. Hamilton, Aziz Nazha, Lisa Rybicki, Valeria Visconte, Jaroslaw P. Maciejewski, Ronald Sobecks, Sudipto Mukherjee, Navneet S. Majhail, Aaron T. Gerds, Mikkael A. Sekeres, Hassan Awada, Jibran Durrani
Publikováno v:
Blood. 134:2716-2716
Both founder and secondary mutations in AML and MDS have prognostic implications that may depend on their rank in subclonal hierarchy. Mutational profiles at relapse after chemotherapy may be different from relapse following alloHCT as a result of th
Autor:
Horst Mueller, Jasmin Mettler, Paul J Bröckelmann, Conrad-Amadeus Voltin, Andreas Engert, Carsten Kobe, Christian Baues, Peter Borchmann, Michael Fuchs, Markus Dietlein
Publikováno v:
Blood. 134:4020-4020
Background: Metabolic tumor volume (MTV) measured by FDG-PET/CT is becoming established as an independent risk factor for treatment failure in Hodgkin lymphoma (HL). Moreover, response to treatment with novel agents including checkpoint inhibitors ma
Autor:
Valentín García Gutiérrez, Julián Sevilla, maria Del Mar Herraez, Nuria García-Ormeña, Rosalia Riaza, Rosa Ayala, Espino Maria Jose, Francisca Ferrer Marin, José Ángel Hernández, Eva Barragán, Elena Ruiz, Vanegas Raul, Luis Felipe Casado Montero, Cristina Seri, Ricardo Sanchez, Pilar Bravo, Juan Luis Steegmann, Joaquin Martinez-Lopez, sanchez-Calero Jorge, María Monteagudo, Lucia Villalon, Eduardo Anguita, Elena Magro, Gonzalo Carreño Gomez-Tarragona, Beatriz Cuevas
Publikováno v:
Blood. 134:5368-5368
Background: Kinase domain (KD) mutations is a common resistance mechanism, secondary to the tyrosine-kinase inhibitors (ITKs) treatment in the case of chronic myeloid leukemia (CML) and Philadelphia (Ph)-positive acute lymphoblastic leukemia (ALL) pa